Pan-cancer analysis of TMED2: unraveling potential immune characteristics and prognostic value in cancer therapy

Our plain-English summary of Pan-cancer analysis of TMED2: unraveling potential immune characteristics and prognostic value in cancer therapy, by Z. Wang, C. Sun, P. Wang, et al (Frontiers in Immunology, 2025).

The study

• Authors: Z. Wang, C. Sun, P. Wang, S. Lin, X. Wu, Y. Gu
• Journal: Frontiers in Immunology
• Published: 2025;16:1578627
• Cited by: 7 articles, as counted by NIH iCite
• Read it: PubMed · Publisher · Free full text

Abstract

Background: Transmembrane emp24 domain-containing protein 2 (TMED2) is involved in the sorting and transport of proteins between the Golgi apparatus and the endoplasmic reticulum. Recent research has identified a close association between TMED2 and tumorigenesis, yet its regulatory role and underlying mechanisms in pan-cancer signaling pathways remain unexplored.

Methods: We conducted a comprehensive pan-cancer analysis of TMED2 using multiple public databases. These analyses included assessments of prognostic significance, gene mutations, pathway enrichment, single-cell sequencing analysis, immune characteristics, co-expressed gene PPI network analysis, as well as the therapeutic response of TMED2 in immunotherapy and small molecule sensitivity. Finally, we examined the role that TMED2 plays at the cellular level.

Results: Our results show that the mRNA levels of TMED2 differ significantly between cancerous and normal tissues and are closely associated with cancer prognosis. Specifically, in CESC, MESO, LGG, and UVM, overexpression of TMED2 correlates with patient prognosis and various clinical pathological features. TMED2 is significantly associated with immune infiltration (including endothelial cells, neutrophils, dendritic cells, and eosinophils), immune checkpoints (CD274, HAVCR2, PDCD1LG2, and SIGLEC15), and signaling pathways (cell cycle and PI3K/Akt). Single-cell sequencing reveals that TMED2 is predominantly expressed in tumor cells of cervical cancer, glioma, and mesothelioma. Enrichment analysis shows that genes co-expressed with TMED2 are primarily involved in processes like endoplasmic reticulum stress and the ERAD pathway. Furthermore, cellular studies indicated that TMED2 expression promotes the growth, migration and invasion of glioma cells.

Conclusion: Our integrated analysis suggests that targeting TMED2, along with its associated genes and signaling pathways, could represent a new strategy for cancer immune treatment.

Copyright © 2025 Wang, Sun, Wang, Lin, Wu and Gu.

In plain English

This study looked at TMED2, a gene that helps move proteins inside cells, across many cancer types, including mesothelioma. The article does not say whether the mesothelioma was pleural or peritoneal, and it does not discuss asbestos. The authors analyzed public gene-expression data from tumors and normal tissue, single-cell data from cervical cancer, glioma and mesothelioma, and drug-response datasets. They also ran laboratory tests on two glioma cell lines. TMED2 mRNA levels were higher in tumor than normal tissue in many cancers; acute myeloid leukemia was the only one where they were lower. Higher TMED2 was associated with poorer overall survival in nine cancer types, mesothelioma among them. It was also associated with a shorter progression-free interval in five, again including mesothelioma. In the single-cell data, TMED2 was highest in tumor cells. In immunotherapy datasets for five other cancer types, people who did not respond had higher TMED2 levels. Lowering TMED2 in glioma cells reduced their growth and migration. The authors concluded that targeting TMED2 could be a new strategy for cancer immune treatment. They called the analysis preliminary and said more in vitro and in vivo research is needed.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Pan-cancer bioinformatic analysis of public databases, plus laboratory experiments in glioma cell lines
• Who was studied: Tumor and normal tissue data from public databases (TCGA, GTEx, CCLE); single-cell datasets from cervical cancer, glioma and mesothelioma; drug-response datasets; laboratory work on U87 and U251 glioma cell lines. Patient numbers are not given in the text.
• Exposure: Not an asbestos exposure study. The factor studied was the expression level of the TMED2 gene. In the cell experiments, TMED2 was knocked down in glioma cells.
• Main results:
  • In combined TCGA and GTEx data, TMED2 mRNA was upregulated in many cancers compared with normal tissue. Mesothelioma (MESO) is not in that list. Only acute myeloid leukemia (LAML) showed lower TMED2.
  • In the pathological tumor staging of mesothelioma (MESO), TMED2 expression was higher in stages I and IV than in stages II and III.
  • In univariate Cox regression, higher TMED2 expression was associated with poor overall survival in nine cancer types, including mesothelioma (MESO). No hazard ratios are given in the text.
  • Higher TMED2 expression predicted a shorter progression-free interval in ACC, CESC, LGG, MESO and UVM.
  • In single-cell data from cervical cancer, glioma and mesothelioma, TMED2 expression was highest in tumor cells.
  • In most cancers, TMED2 expression correlated positively with infiltration levels of endothelial cells, neutrophils, dendritic cells and eosinophils, and negatively with monocytes.
  • In ROC Plotter immunotherapy datasets for NSCLC, SKCM, HNSC, GBM and BLCA (not mesothelioma), TMED2 expression was higher in non-responders.
  • Across CESC, MESO, LGG and UVM, the authors identified 299 genes co-expressed with TMED2. These were linked to processes such as endoplasmic reticulum stress and ERAD.
  • In U87 and U251 glioma cells, TMED2 knockdown reduced proliferation.
  • In U87 and U251 glioma cells, TMED2 knockdown reduced migration in Transwell assays.
• The authors' conclusion: The authors concluded that targeting TMED2, with its associated genes and signaling pathways, could be a new strategy for cancer immune treatment.
• Limitations the authors state:
  • The authors described their analysis as preliminary.
  • The authors stated that more in vitro and in vivo research is needed to confirm TMED2's function and mechanisms.

Topics

Medical terms in this study, explained in our Lexicon: Carcinogenesis, Immunotherapy, Prognosis, Mesothelioma.

Related studies

• Priming the tumor immune microenvironment with chemo(radio)therapy: A systematic review across tumor types — T. van den Ende, H.G. van den Boorn, et al. (2020)
• Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin — G. Ak, Y. Tada, et al. (2017)
• The prognostic and immunological effects of ZBTB7C across cancers: friend or foe? — X. Chen, Z. Jiang, et al. (2021)
• NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis — J.P. Lai, P.F. Robbins, et al. (2012)
• Pan-cancer analysis shows that TRIP13 as a potential prognostic and immunotherapeutic biomarker for multiple cancer types including LIHC and LUAD — C. Li, Z. Zhou, et al. (2025)
• Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas — O. Kaufmann, E. Fietze, et al. (2001)

Browse more research in Frontiers in Immunology, or return to medical research.